{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T11:55:56Z","timestamp":1765540556588,"version":"3.48.0"},"reference-count":46,"publisher":"Walter de Gruyter GmbH","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jbcpp-2018-0184_s_999_w2aab3b7c27b1b6b1aab1c14b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Combined oral contraceptive (COC) use has been associated with an increased risk of insulin resistance (IR) and other adverse cardiovascular events, despite efforts to reduce the dosage and\/or progestin type. COC containing drospirenone (DRSP) is an analog of spironolactone, hence its antimineralocorticoid and antiandrogenic characteristics have been deemed beneficial, although the benefits and\/or negative outcome of its usage have not been fully elucidated. We therefore hypothesized that COC with DRSP component will not affect glucose regulation and circulating corticosterone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2018-0184_s_998_w2aab3b7c27b1b6b1aab1c14b2Aa\">\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Ten-week-old female Wistar rats were divided into three groups: control (CON), ethinylestradiol\/drospirenone COC (EE\/DRSP)-treated, and ethinylestradiol\/levonorgestrel COC (EE\/LN)-treated rats. The treatment lasted for 8 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2018-0184_s_997_w2aab3b7c27b1b6b1aab1c14b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Results showed that with the exception of lipid profiles, EE\/LN but not EE\/DRSP COC treatment affected body weight, glucose tolerance, plasma insulin, corticosterone, (IR), and pancreatic \u03b2-cell dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2018-0184_s_996_w2aab3b7c27b1b6b1aab1c14b4Aa\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Taken together, the findings showed that the beneficial effect of EE\/DRSP could possibly be through the DRSP component. The result also implies that COCs containing DRSP may be a better and safer means of contraception than those with LN with less cardiovascular risks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jbcpp-2018-0184","type":"journal-article","created":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T05:40:53Z","timestamp":1567143653000},"source":"Crossref","is-referenced-by-count":6,"title":["Drospirenone-containing oral contraceptives do not affect glucose regulation and circulating corticosterone"],"prefix":"10.1515","volume":"30","author":[{"given":"Oluwaseun A.","family":"Adeyanju","sequence":"first","affiliation":[{"name":"Department of Physiology, College of Health Sciences , University of Ilorin , Ilorin 240003 , Nigeria"},{"name":"Cardiometabolic Research Unit, Department of Physiology , Afe Babalola University , Ado-Ekiti , Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence A.","family":"Olatunji","sequence":"additional","affiliation":[{"name":"Department of Physiology, College of Health Sciences , University of Ilorin , PMB 1515 , Ilorin 240003 , Nigeria , Phone: +2348035755360"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2019,8,30]]},"reference":[{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_001_w2aab3b7c27b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Cameron A. The metabolic syndrome: validity and utility of clinical definitions for cardiovascular disease and diabetes risk prediction. Maturitas 2010;65:117\u201321.","DOI":"10.1016\/j.maturitas.2009.11.026"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_002_w2aab3b7c27b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Wilson PW, D\u2019agostino RB, Parise H, Sulivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005;112:3066\u201372.","DOI":"10.1161\/CIRCULATIONAHA.105.539528"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_003_w2aab3b7c27b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Wang J, Ruotsalainen S, Moilanen L, Lepisto P, Laakso M, Kuusisto J. The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. Eur Heart J 2007;28:857\u201364.","DOI":"10.1093\/eurheartj\/ehl524"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_004_w2aab3b7c27b1b6b1ab2b2b4Aa","unstructured":"Centers for Disease Control and Prevention (CDC). National diabetes statistics report [Internet]. Atlanta, GA: Centers for Disease Control and Prevention, 2014."},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_005_w2aab3b7c27b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Sasso FC, Carbonara O, Nasti R, Campana B, Marfella R, Torella M, et al. Glucose metabolism and coronary heart disease in patients with normal glucose tolerance. J Am Med Assoc 2004;291:1857\u201363.","DOI":"10.1001\/jama.291.15.1857"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_006_w2aab3b7c27b1b6b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006;29:1130\u20139.","DOI":"10.2337\/dc05-2179"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_007_w2aab3b7c27b1b6b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Rhen T, Cidlowski JA. Anti-inflammatory action of glucocorticoids \u2013 new mechanisms for old drugs. N Engl J Med 2005;353:1711\u201323.","DOI":"10.1056\/NEJMra050541"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_008_w2aab3b7c27b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Dekkers OM, Horvath-Puho E, Jorgensen JO, Cannegieter SC, Ehrenstein V, Vandenbroucke JP, et al. Multisystem morbidity and mortality in Cushing\u2019s syndrome: a cohort study. J Clin Endocrinol Metab 2013;98:2277\u201384.","DOI":"10.1210\/jc.2012-3582"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_009_w2aab3b7c27b1b6b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Coelho MC, Santos CV, Vieira Neto L, Gadelha MR. Adverse effects of glucocorticoids: coagulopathy. Eur J Endocrinol 2015;173:M11\u201321.","DOI":"10.1530\/EJE-15-0198"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_010_w2aab3b7c27b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Shufelt CL, Merz CN. Contraceptive hormone use and cardiovascular disease. J Am Coll Cardiol 2009;53:221\u201331.","DOI":"10.1016\/j.jacc.2008.09.042"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_011_w2aab3b7c27b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Olatunji LA, Omolekulo TE, Usman TO, Kim I. Improvement of oral contraceptive-induced glucose dysregulation and dyslipidemia by valproic acid is independent of circulating corticosterone. Arch Physiol Biochem 2016;122:123\u20139.","DOI":"10.3109\/13813455.2016.1151892"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_012_w2aab3b7c27b1b6b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Adeyanju OA, Michael OS, Soladoye AO, Olatunji LA. Blockade of mineralocorticoid receptor ameliorates oral contraceptive-induced insulin resistance by suppressing elevated uric acid and glycogen synthase kinase-3 instead of circulating mineralocorticoid. Arch Physiol Biochem 2018. Available at: https:\/\/doi.org\/10.1080\/13813455.2018.1509220 (ahead of print). Accessed January 2019.","DOI":"10.1080\/13813455.2018.1509220"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_013_w2aab3b7c27b1b6b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Baillargeon JP, McClish DK, Essah PA, Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 2014;90:3863\u201370.","DOI":"10.1210\/jc.2004-1958"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_014_w2aab3b7c27b1b6b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Practice Committee of the American Society for Reproductive Medicine. Hormonal contraception: recent advances and controversies. Fertil Steril 2008;90:103\u201313.","DOI":"10.1016\/j.fertnstert.2008.08.093"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_015_w2aab3b7c27b1b6b1ab2b2c15Aa","unstructured":"Centers for Disease Control and Prevention. US medical eligibility criteria for contraceptive use. Adapted from the World Health Organization medical eligibility criteria for contraceptive use. 4th edition. MMWR Early Release 2010;59:1\u20136."},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_016_w2aab3b7c27b1b6b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Giribela CR, Melo NR, Silva RC, Hong VM, Guerra GM, Baracat EC, et al. A combined oral contraceptive containing drospirenone changes neither endothelial function nor hemodynamic parameters in healthy young women: a prospective clinical trial. Contraception 2012;86:35\u201341.","DOI":"10.1016\/j.contraception.2011.08.017"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_017_w2aab3b7c27b1b6b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Palacios S, Foidart JM, Genazzani AR. Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism. Maturitas 2006;55:297\u2013307.","DOI":"10.1016\/j.maturitas.2006.07.009"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_018_w2aab3b7c27b1b6b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol Cell Endocrinol 2004;217:255\u201361.","DOI":"10.1016\/j.mce.2003.10.030"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_019_w2aab3b7c27b1b6b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Guido M, Romualdi D, Giuliani M, Suriano R, Selvaggi L, Apa R, et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 2004;89:2817\u201323.","DOI":"10.1210\/jc.2003-031158"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_020_w2aab3b7c27b1b6b1ab2b2c20Aa","doi-asserted-by":"crossref","unstructured":"Pehlivanov B, Mitkov M. Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome. Eur J Contracept Reprod Health Care 2007;12:30\u20135.","DOI":"10.1080\/13625180600983082"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_021_w2aab3b7c27b1b6b1ab2b2c21Aa","doi-asserted-by":"crossref","unstructured":"Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Risk of thromboembolism in women taking ethinylestradiol\/drospirenone and other oral contraceptives. Obstet Gynecol 2007;110:587\u201393.","DOI":"10.1097\/01.AOG.0000279448.62221.a8"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_022_w2aab3b7c27b1b6b1ab2b2c22Aa","unstructured":"Gordon RJ. Viscosity considerations in the determination of regional circulatory adjustments to anemia. Circ Res 1972;31:805\u201312."},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_023_w2aab3b7c27b1b6b1ab2b2c23Aa","doi-asserted-by":"crossref","unstructured":"Olatunji LA, Oyeyipo IP, Usman TO. Effect of a high-fructose diet on glucose tolerance, plasma lipid and hemorhaeological parameters during oral contraceptive administration in female rats. Clin Hemorheol Microcirc 2013;54:23\u201331.","DOI":"10.3233\/CH-2012-1561"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_024_w2aab3b7c27b1b6b1ab2b2c24Aa","doi-asserted-by":"crossref","unstructured":"Olatunji LA, Michael OS, Adewumi FO, Aiyegboyin IJ, Olatunji VA. Combined estrogen-progestogen but not progestogen-only oral contraceptive alters glucose tolerance and plasma lipid profile in female rats. Pathophysiology 2012;19:29\u201334.","DOI":"10.1016\/j.pathophys.2011.09.001"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_025_w2aab3b7c27b1b6b1ab2b2c25Aa","doi-asserted-by":"crossref","unstructured":"Succurro E, Arturi F, Lugara M, Grembiale A, Fiorentino TV, Caruso V, et al. One hour postload plasma glucose levels are associated with kidney dysfunction. Clin J Am Soc Nephrol 2010;5:1922\u20137.","DOI":"10.2215\/CJN.03240410"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_026_w2aab3b7c27b1b6b1ab2b2c26Aa","doi-asserted-by":"crossref","unstructured":"Bianchi C, Miccoli R, Trombetta M, Giorgino F, Frontoni S, Faloia E, et al. Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired \u03b2-cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study. J Clin Endocrinol Metab 2013;98:2100\u20135.","DOI":"10.1210\/jc.2012-3971"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_027_w2aab3b7c27b1b6b1ab2b2c27Aa","doi-asserted-by":"crossref","unstructured":"DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010;53:1270\u201387.","DOI":"10.1007\/s00125-010-1684-1"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_028_w2aab3b7c27b1b6b1ab2b2c28Aa","doi-asserted-by":"crossref","unstructured":"Nguyen QM, Srinivasan SR, Xu JH, Chen W, Berenson GS. Fasting plasma glucose levels within the normoglycemic range in childhood as a predictor of prediabetes and type 2 diabetes in adulthood: the Bogalusa heart study. Arch Pediatr Adolesc Med 2010;164:124\u20138.","DOI":"10.1001\/archpediatrics.2009.268"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_029_w2aab3b7c27b1b6b1ab2b2c29Aa","doi-asserted-by":"crossref","unstructured":"Wang H, Shara NM, Calhoun D, Umans JG, Lee ET, Howard BV. Incidence rates and predictors of diabetes in those with prediabetes: the strong heart study. Diab\/Metab Res Rev 2010;26:378\u201385.","DOI":"10.1002\/dmrr.1089"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_030_w2aab3b7c27b1b6b1ab2b2c30Aa","doi-asserted-by":"crossref","unstructured":"Abdul-Ghani MA, Williams K, DeFronzo RA, Stern M. What is the best predictor of future type 2 diabetes? Diabetes Care 2007;30:1544\u20138.","DOI":"10.2337\/dc06-1331"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_031_w2aab3b7c27b1b6b1ab2b2c31Aa","doi-asserted-by":"crossref","unstructured":"Fonseca VA. Early identification and treatment of insulin resistance: impact on subsequent prediabetes and type 2 diabetes. Clin Cornerstone 2010;8:S7\u201318.","DOI":"10.1016\/S1098-3597(07)80017-2"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_032_w2aab3b7c27b1b6b1ab2b2c32Aa","doi-asserted-by":"crossref","unstructured":"White WB, Hanes V, Chauhan V, Pitt B. Effects of a new hormone therapy, drospirenone and 17-betaestradiol, in postmenopausal women with hypertension. Hypertension 2006;48:246\u201353.","DOI":"10.1161\/01.HYP.0000232179.60442.84"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_033_w2aab3b7c27b1b6b1ab2b2c33Aa","doi-asserted-by":"crossref","unstructured":"Belcastro V, D\u2019Egidio C, Striano P, Verrotti A. Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Res 2013;107:1\u20138.","DOI":"10.1016\/j.eplepsyres.2013.08.016"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_034_w2aab3b7c27b1b6b1ab2b2c34Aa","doi-asserted-by":"crossref","unstructured":"Musso C, Graffigna M, Soutelo J, Honfi M, Ledesma L, Miksztowicz V, et al. Cardiometabolic risk factors as apolipoprotein B, triglyceride\/HDL-cholesterol ratio and C-reactive protein, in adolescents with and without obesity: cross sectional study in middle class suburban children. Pediatr Diab 2011;12:229\u201334.","DOI":"10.1111\/j.1399-5448.2010.00710.x"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_035_w2aab3b7c27b1b6b1ab2b2c35Aa","doi-asserted-by":"crossref","unstructured":"Shulman LP. A review of drospirenone for safety and tolerability and effects on endometrial safety and lipid parameters contrasted with medroxyprogesterone acetate, levonorgestrel, and micronized progesterone. J Women\u2019s Health 2006;15:584\u201390.","DOI":"10.1089\/jwh.2006.15.584"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_036_w2aab3b7c27b1b6b1ab2b2c36Aa","doi-asserted-by":"crossref","unstructured":"Foidart JM, Faustmann T. Advances in hormone replacement therapy: weight benefits of drospirenone, a 17-alphaspirolactone-derived progestogen. Gynecol Endocrinol 2007;23:692\u20139.","DOI":"10.1080\/09513590701582323"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_037_w2aab3b7c27b1b6b1ab2b2c37Aa","doi-asserted-by":"crossref","unstructured":"Nisenbaum MG, Melo NR, Giribela CR, de Morais TL, Guerra GM, de Angelis K, et al. Effects of a contraceptive containing drospirenone and ethinyl estradiol on blood pressure and autonomic tone: a prospective controlled clinical trial. Eur J Obstet Gynecol Reprod Biol 2014;175:62\u20136.","DOI":"10.1016\/j.ejogrb.2014.01.006"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_038_w2aab3b7c27b1b6b1ab2b2c38Aa","doi-asserted-by":"crossref","unstructured":"White WB, Pitt B, Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17-beta-estradiol, a novel hormone treatment in postmenopausal woman with stage 1 hypertension. Circulation 2005;112:1979\u201380.","DOI":"10.1161\/CIRCULATIONAHA.104.501502"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_039_w2aab3b7c27b1b6b1ab2b2c39Aa","doi-asserted-by":"crossref","unstructured":"Moro F, Morciano A, Tropea A, Sagnella F, Palla C, Scarinci E, et al. Effects of drospirenone-ethinylestradiol and\/or metformin on CD4 + CD28null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reprod Sci 2013;20:1508\u201317.","DOI":"10.1177\/1933719113488444"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_040_w2aab3b7c27b1b6b1ab2b2c40Aa","doi-asserted-by":"crossref","unstructured":"Woodward M, Rumley A, Tunstall-pedoe H, Lowe GD. Associations of blood rheology and interleukin-6 with cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 1999;104:246\u201357.","DOI":"10.1046\/j.1365-2141.1999.01158.x"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_041_w2aab3b7c27b1b6b1ab2b2c41Aa","doi-asserted-by":"crossref","unstructured":"Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh artery study. Circulation 2007;115:2119\u201327.","DOI":"10.1161\/CIRCULATIONAHA.106.635029"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_042_w2aab3b7c27b1b6b1ab2b2c42Aa","doi-asserted-by":"crossref","unstructured":"Koenig W, Sund M, Filipiak B, D\u00f6ring A, L\u00f6wel H, Ernst E. Plasma viscosity and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 1998;18:768\u201372.","DOI":"10.1161\/01.ATV.18.5.768"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_043_w2aab3b7c27b1b6b1ab2b2c43Aa","doi-asserted-by":"crossref","unstructured":"Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96:23\u201343.","DOI":"10.1016\/S0163-7258(02)00297-8"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_044_w2aab3b7c27b1b6b1ab2b2c44Aa","doi-asserted-by":"crossref","unstructured":"Fransson L, Franz\u00e9n S, Rosengren V, Wolbert P, Sj\u00f6holm \u00c5, Orts\u00e4ter H. \u03b2-cell adaptation in a mouse model of glucocorticoid-induced metabolic syndrome. J Endocrinol 2013;18:JOE-13.","DOI":"10.1530\/JOE-13-0189"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_045_w2aab3b7c27b1b6b1ab2b2c45Aa","doi-asserted-by":"crossref","unstructured":"Preston RA, White WB, Pitt B, Bakris G, Norris PM, Hanes V. Effects of drospirenone\/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. AJH 2005;18:797\u2013804.","DOI":"10.1016\/j.amjhyper.2004.12.003"},{"key":"2025121209140538140_j_jbcpp-2018-0184_ref_046_w2aab3b7c27b1b6b1ab2b2c46Aa","doi-asserted-by":"crossref","unstructured":"Seckl JR. 11\u03b2-hydroxysteroid dehydrogenase isoforms and their implications for blood pressure regulation. Eur J Clin Invest 1993;23:589\u2013601.","DOI":"10.1111\/j.1365-2362.1993.tb00720.x"}],"container-title":["Journal of Basic and Clinical Physiology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/jbcpp.2019.30.issue-5\/jbcpp-2018-0184\/jbcpp-2018-0184.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2018-0184\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2018-0184\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T11:51:38Z","timestamp":1765540298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2018-0184\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,30]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,8,30]]},"published-print":{"date-parts":[[2019,9,25]]}},"alternative-id":["10.1515\/jbcpp-2018-0184"],"URL":"https:\/\/doi.org\/10.1515\/jbcpp-2018-0184","relation":{},"ISSN":["2191-0286","0792-6855"],"issn-type":[{"type":"electronic","value":"2191-0286"},{"type":"print","value":"0792-6855"}],"subject":[],"published":{"date-parts":[[2019,8,30]]},"article-number":"20180184"}}